Submission of Declaration of Conformity for CE mark for Avacta’s rapid antigen test
Avacta Group PLC (AVCT.L) AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
Omega Diagnostics Gp (ODX.L) Positive data for Mologic COVID-19 antigen test
Further positive data for Mologic COVID-19 lateral flow antigen test
Omega Diagnostics Gp (ODX.L) Launch of VISITECT® COVID-19 Antigen & Update
Rapid diagnostic test for visual detection of SARS-CoV-2 antigen
Avacta Group PLC (AVCT.L) Final Results
Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
Avacta Group PLC (AVCT.L) Directorate Change
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down
Omega Diagnostics Gp (ODX.L) CE-Mark: Mologic COVID19 lateral flow antigen test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd’s (‘Mologic’) lateral flow antigen test for COVID-19, to
Omega Diagnostics Gp (ODX.L) UK Public Sector Contract disclosure
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that a UK Public Sector contract disclosure has been published yesterday in relation to
Avacta Group PLC (AVCT.L) Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Omega Diagnostics Gp (ODX.L) Contract with Screen4
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Avacta Group PLC (AVCT.L) Significant momentum in both Diagnostics and Therapeutics Divisions
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
